A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.

ABSTRACT:

SUBMITTER: Mikhael J 

PROVIDER: S-EPMC8116334 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature